BTMD · XBRL financial data

biote financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BTMD's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	139,396	164,957	185,360	197,191	192,219
Selling, general and administrative	49,054	165,502	98,826	107,450	101,810
Operating income (loss)	(3,322)	(60,722)	28,657	31,611	35,551
Other income (expense)	—	29	(16)	11	(29)
Income tax expense (benefit)	0	388	2,682	970	5,987
Net income (loss)	11,113	(969)	3,316	3,157	27,045
Earnings per share, basic USD per share	—	(0.12)	0.13	0.09	0.86
Earnings per share, diluted USD per share	—	(0.12)	0.13	0.09	0.74
Weighted average shares, basic thousands of shares	—	8,059	25,709	34,271	31,283
Weighted average shares, diluted thousands of shares	—	8,059	25,709	34,271	36,667

Fiscal years (BTMD's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	130	79,231	89,002	39,342	24,123
Accounts receivable	5,231	6,948	6,809	7,631	6,868
Inventory	9,615	11,183	17,307	14,845	19,064
Prepaid and other current assets	5,473	3,816	9,225	6,309	4,615
Total current assets	452	101,178	122,343	68,127	54,670
Property and equipment, net	2,335	1,504	1,218	6,973	10,753
Right-of-use asset	356	2,052	1,877	3,246	2,701
Goodwill	—	—	—	5,833	5,833
Total assets	318,033	111,645	155,295	122,370	107,613
Accounts payable	281	4,112	4,155	5,813	6,826
Accrued liabilities	1,830	6,274	8,497	11,293	9,806
Current portion of long-term debt	5,000	6,250	6,250	6,250	6,250
Total current liabilities	2,272	18,766	22,215	51,514	44,991
Long-term debt	31,963	112,086	106,630	101,199	95,782
Lease liability, non-current	127	1,927	1,680	2,890	2,298
Total liabilities	23,163	169,919	191,841	224,570	158,010
Accumulated deficit	(22,631)	(44,460)	(29,391)	(100,297)	(49,549)
Total stockholders' equity	(22,630)	(44,459)	(29,397)	(105,928)	(58,539)
Total liabilities and equity	318,033	111,645	155,295	122,370	107,613
Common shares outstanding (cover page) thousands of shares	—	58,221	—	—	—

Fiscal years (BTMD's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	11,113	(969)	3,316	3,157	27,045
Stock-based compensation	—	82,180	9,057	8,735	8,921
Depreciation and amortization	1,400	2,199	2,994	3,574	3,670
Net cash from operating activities	(1,371)	(9,157)	26,883	45,243	35,194
Purchases of property and equipment	1,448	333	359	6,430	5,015
Net cash from investing activities	(317,500)	(1,838)	(2,713)	(18,798)	(6,864)
Proceeds from issuing common stock	0	—	—	—	—
Share repurchases	—	—	—	5,599	3,365
Dividends paid	11,402	12,886	8,694	4,744	1,727
Net cash from financing activities	319,000	63,460	(14,380)	(76,083)	(43,555)
Net change in cash	9,558	52,465	9,771	(49,660)	(15,219)

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
biote	11,168	44,232	(1,176)*	not reported	9.5 quarters	Q2 FY26 10-QJun 30, 2026
Assembly Biosciences	32,286	not reported	(15,488)*	20.4M	20.7 quarters	Q2 FY26 10-QJun 30, 2026
Milestone Pharmaceuticals	169,728	559	(22,714)*	124.5M	7.5 quarters	Q2 FY26 10-QJun 30, 2026
DiaMedica Therapeutics	5,129	not reported	(8,114)*	53.9M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Carisma Therapeutics	2,777	45,300	1,908*	41.8M	—	Q3 FY25 10-QSep 30, 2025
Larimar Therapeutics	92,687	not reported	(44,030)*	103.9M	3.5 quarters	Q2 FY26 10-QJun 30, 2026
Ironwood Pharmaceuticals	86,376	133,040	67,401*	165.6M	—	Q3 FY26 10-QSep 30, 2026
Vaxart	50,929	27,185	2,778*	242.8M	—	Q2 FY26 10-QJun 30, 2026
Achieve Life Sciences	47,958	not reported	(10,777)*	102.9M	17.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.